High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3

High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature Immunology 2014, Vol.15 (2), p.152
Hauptverfasser: De Nardo, Dominic, Labzin, Larisa I, Kono, Hajime, Seki, Reiko, Schmidt, Susanne V, Beyer, Marc, Xu, Dakang, Zimmer, Sebastian, Lahrmann, Catharina, Schildberg, Frank A, Vogelhuber, Johanna, Kraut, Michael, Ulas, Thomas, Kerksiek, Anja, Krebs, Wolfgang, Bode, Niklas, Grebe, Alena, Fitzgerald, Michael L, Hernandez, Nicholas J, Williams, Bryan R.G, Knolle, Percy, Kneilling, Manfred, Rocken, Ma, Lutjohann, Dieter, Wright, Samuel D, Schultze, Joachim L, Latz, Eicke
Format: Report
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional regulator ATF3, as an HDL-inducible target gene in macrophages that downregulates the expression of Toll-like receptor (TLR)-induced proinflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of new HDL-based therapies.
ISSN:1529-2908
DOI:10.1038/ni.2784